Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients

Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients

The durability of the immunogenicity elicited by three doses of mRNA-based BNT162b2 and whole-virus inactivated CoronaVac in patients with neuromuscular diseases, particularly those on immunosuppressive drugs and variants of concern, has not been well-established. Our goal was to evaluate medium-ter...

Full description

Saved in:
Bibliographic Details
Main Authors: Michael Kwan Leung Yu, Sophelia Hoi Shan Chan, Daniel Leung, Samuel Cheng, Leo Chi Hang Tsang, Tsz Chun Kwan, Kaiyue Zhang, Xiwei Wang, Wenwei Tu, Malik Peiris, Yu Lung Lau, Jaime S. Rosa Duque
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
BNT162b2
COVID-19
CoronaVac
neuromuscular diseases
immunogenicity
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2424615
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items